XML 75 R53.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Collaboration and Other Agreements, NIAID Contract (Details) - NIAID [Member] $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2015 USD ($) Molecule
Collaboration And Other Agreements [Line Items] |
Agreement beginning date | September 15, 2015
Commercialization of molecules | Molecule | 2
Base period value | $ 7.5
Recognized revenue under agreement | $ 0.2
Agreement end date | September 14, 2022
Maximum [Member] |
Collaboration And Other Agreements [Line Items] |
Additional development funding options | $ 17.0
Total potential value | $ 24.5

X
- Definition Additional funding available under agreement at counterparty's option + References No definition available. + Details
Name: | mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Date on which the Company and collaborator collaboration agreement ends. + References No definition available. + Details
Name: | mgnx_CollaborationAndLicenseAgreementEndingDate
Namespace Prefix: | mgnx_
Data Type: | invest:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Date on which the Company entered into agreement. + References No definition available. + Details
Name: | mgnx_CollaborationAndOtherAgreementEnteredDate
Namespace Prefix: | mgnx_
Data Type: | invest:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Funded value of base period + References No definition available. + Details
Name: | mgnx_FundedValueOfBasePeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of molecules to be developed and commercialized as per collaboration. + References No definition available. + Details
Name: | mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Refers to total potential value under agreement. + References No definition available. + Details
Name: | mgnx_TotalPotentialValueUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |